SLC25A22

Across TCGA pan-cancer cohorts, SLC25A22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC25A22 data layer compared with 29 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC25A22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A22 expression acts as an unfavorable survival marker.

HNSC, COAD, and LIHC are the cancer types where SLC25A22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.013	0.746	<.001	24	view →
COAD	OS	Median	All	0.267	0.803	<.001	18	view →
LIHC	OS	Median	All	0.188	0.690	.005	15	view →
BRCA	DFS	Median	All	0.745	0.949	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC25A22–HNSC (OS)

Open the HNSC breakdown →